909 related articles for article (PubMed ID: 31388093)
21. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
Stecher B
Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
[TBL] [Abstract][Full Text] [Related]
22. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease.
Sun MF; Shen YQ
Ageing Res Rev; 2018 Aug; 45():53-61. PubMed ID: 29705121
[TBL] [Abstract][Full Text] [Related]
23. Molecular Paths Linking Metabolic Diseases, Gut Microbiota Dysbiosis and Enterobacteria Infections.
Serino M
J Mol Biol; 2018 Mar; 430(5):581-590. PubMed ID: 29374557
[TBL] [Abstract][Full Text] [Related]
24. The metabolic and vascular protective effects of olive (Olea europaea L.) leaf extract in diet-induced obesity in mice are related to the amelioration of gut microbiota dysbiosis and to its immunomodulatory properties.
Vezza T; Rodríguez-Nogales A; Algieri F; Garrido-Mesa J; Romero M; Sánchez M; Toral M; Martín-García B; Gómez-Caravaca AM; Arráez-Román D; Segura-Carretero A; Micol V; García F; Utrilla MP; Duarte J; Rodríguez-Cabezas ME; Gálvez J
Pharmacol Res; 2019 Dec; 150():104487. PubMed ID: 31610229
[TBL] [Abstract][Full Text] [Related]
25. Connection between gut microbiome and the development of obesity.
Zhi C; Huang J; Wang J; Cao H; Bai Y; Guo J; Su Z
Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):1987-1998. PubMed ID: 31367997
[TBL] [Abstract][Full Text] [Related]
26. Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders.
Rajani C; Jia W
Clin Sci (Lond); 2018 Apr; 132(7):791-811. PubMed ID: 29661926
[TBL] [Abstract][Full Text] [Related]
27. Intestinal Barrier in Human Health and Disease.
Di Tommaso N; Gasbarrini A; Ponziani FR
Int J Environ Res Public Health; 2021 Dec; 18(23):. PubMed ID: 34886561
[TBL] [Abstract][Full Text] [Related]
28. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation.
Hendrikx T; Schnabl B
J Intern Med; 2019 Jul; 286(1):32-40. PubMed ID: 30873652
[TBL] [Abstract][Full Text] [Related]
29. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.
Geurts L; Neyrinck AM; Delzenne NM; Knauf C; Cani PD
Benef Microbes; 2014 Mar; 5(1):3-17. PubMed ID: 23886976
[TBL] [Abstract][Full Text] [Related]
30. Are gut dysbiosis, barrier disruption, and endotoxemia related to adipose tissue dysfunction in metabolic disorders? Overview of the mechanisms involved.
Rosendo-Silva D; Viana S; Carvalho E; Reis F; Matafome P
Intern Emerg Med; 2023 Aug; 18(5):1287-1302. PubMed ID: 37014495
[TBL] [Abstract][Full Text] [Related]
31. Microbiota and metabolic diseases.
Pascale A; Marchesi N; Marelli C; Coppola A; Luzi L; Govoni S; Giustina A; Gazzaruso C
Endocrine; 2018 Sep; 61(3):357-371. PubMed ID: 29721802
[TBL] [Abstract][Full Text] [Related]
32. [The intestinal microbiome and metabolic diseases : From obesity to diabetes and nonalcoholic steatohepatitis].
Bischoff SC
Internist (Berl); 2017 May; 58(5):441-448. PubMed ID: 28432400
[TBL] [Abstract][Full Text] [Related]
33. Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?
Debédat J; Amouyal C; Aron-Wisnewsky J; Clément K
Semin Immunopathol; 2019 Jul; 41(4):461-475. PubMed ID: 31025085
[TBL] [Abstract][Full Text] [Related]
34. Impaired Intestinal Barrier and Tissue Bacteria: Pathomechanisms for Metabolic Diseases.
Massier L; Blüher M; Kovacs P; Chakaroun RM
Front Endocrinol (Lausanne); 2021; 12():616506. PubMed ID: 33767669
[TBL] [Abstract][Full Text] [Related]
35. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury.
Frazier TH; DiBaise JK; McClain CJ
JPEN J Parenter Enteral Nutr; 2011 Sep; 35(5 Suppl):14S-20S. PubMed ID: 21807932
[TBL] [Abstract][Full Text] [Related]
36. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease.
Bibbò S; Ianiro G; Dore MP; Simonelli C; Newton EE; Cammarota G
Mediators Inflamm; 2018; 2018():9321643. PubMed ID: 29563854
[TBL] [Abstract][Full Text] [Related]
37. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
[TBL] [Abstract][Full Text] [Related]
38. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
Rizzetto L; Fava F; Tuohy KM; Selmi C
J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
[TBL] [Abstract][Full Text] [Related]
39. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis.
Nishikawa H; Enomoto H; Nishiguchi S; Iijima H
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32722100
[TBL] [Abstract][Full Text] [Related]
40. Research digest: reshaping the gut microbiota.
Li J; Hu FB
Lancet Diabetes Endocrinol; 2019 Sep; 7(9):671. PubMed ID: 31439276
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
